CFO of Bicara Therapeutics (BCAX) receives 125,000 stock options at $16.76

Rhea-AI Filing Summary

Bicara Therapeutics reported that its Chief Financial Officer, Hyep Ivan, received a grant of stock options on February 2, 2026. The award covers 125,000 stock options, each allowing the purchase of one share of common stock at an exercise price of $16.76 per share.

The options vest in sixteen equal quarterly installments after February 2, 2026, and require the CFO’s continued service on each vesting date. Following this grant, the reporting person beneficially owns 125,000 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hyep Ivan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	125,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 125,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hyep Ivan

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.76	02/02/2026		A		125,000		(1)	02/02/2036	Common Stock	125,000	$0	125,000	D

Explanation of Responses:

1. The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

	/s/ Lara Meisner, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bicara Therapeutics (BCAX) report for its CFO?

Bicara Therapeutics reported a stock option grant to its Chief Financial Officer, Hyep Ivan. On February 2, 2026, he received 125,000 stock options to buy common shares at an exercise price of $16.76 per share under a direct ownership arrangement.

What are the key terms of the Bicara Therapeutics (BCAX) CFO stock option grant?

The CFO received 125,000 stock options with an exercise price of $16.76 per share. These options relate to Bicara common stock and were granted on February 2, 2026, with the entire amount held directly after the reported transaction.

How do the Bicara Therapeutics (BCAX) CFO’s options vest over time?

The stock options vest in sixteen equal quarterly installments after February 2, 2026. Each quarter, one-sixteenth of the 125,000 options vests, conditioned on the CFO’s continued service with Bicara on each applicable vesting date.

How many Bicara Therapeutics (BCAX) derivative securities does the CFO own after this filing?

After the transaction, the CFO beneficially owns 125,000 derivative securities, all relating to stock options on Bicara common stock. The filing shows these options are held under direct ownership, with no indicated indirect holding entity or shared beneficial ownership.

What is the expiration date of the Bicara Therapeutics (BCAX) CFO stock options?

The reported stock options granted to the CFO expire on February 2, 2036. This provides a long exercise window, during which vested options can be used to purchase Bicara common stock at the fixed exercise price of $16.76 per share.

Who authorized and signed the Bicara Therapeutics (BCAX) Form 4 for the CFO’s grant?

The Form 4 was signed by Lara Meisner as Attorney-in-Fact on February 4, 2026. This indicates the filing was submitted on behalf of the reporting person, CFO Hyep Ivan, under a previously granted power of attorney arrangement.